You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic to Grow on Strong Fundamentals, High Costs a Woe
On Apr 3, we issued an updated research report on Medtronic plc (MDT - Free Report) . While we are encouraged by the global acceptance of the company’s advanced therapies, its escalating costs and expenses raise concerns. The company has a Zacks Rank #3 (Hold).
On a positive note, we are upbeat about Medtronic’s recently-launched restructuring initiative called Enterprise Excellence plan, aimed at $3-billion annual growth run rate savings by the end of fiscal 2022. Per the company, this new program has been designed to increase its effectiveness and growth-related reinvestment ability along with a consistent boost to margin expansion and driving the EPS leverage.
Also, a gradually stabilizing movement witnessed in the global Cardiac Rhythm & Heart Failure (CRHF) market bodes well for further improvement in the coming quarters.
Medtronic PLC Price
Medtronic PLC Price | Medtronic PLC Quote
Meanwhile, at the end of third-quarter fiscal 2018, Medtronic noted that it has successfully met its $850 million Covidien synergy commitments in time. Significantly, this comes under one of the company’s four priorities, which is, ‘optimize’. Per this commitment, Medtronic has started to deliver $225-$250 million in cost synergies and $850 million in annual savings by the end of fiscal 2018.
On the flip side, shares of Medtronic have underperformed the broader industry over the past three months. The stock has lost 8% versus the broader industry’s 2.5% gain.
The company has been exposed to escalating costs and expenses, weighing heavily on its margins. Its reiteration of 2018 guidance despite a favorable foreign currency translation forecast dampens investors’ confidence in the stock.
A few better-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , athenahealth, Inc. and Edwards Lifesciences Corporation (EW - Free Report) .
Bio-Rad Laboratories sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. It has a long-term expected earnings growth rate of 20%.
athenahealth is a Zacks #1 Ranked player. It has a long-term expected earnings growth rate of 21.5%.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.1% and a Zacks Rank #2 (Buy).
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>